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The extraordinarily high incidence of cancers of many different varieties-carcinomas and
lymphomas-in organ-transplant patients being maintained for long periods of time with im-
munosuppressive drugs is briefly reviewed. The role of immunosurveillance as a primary
defense mechanism against cancer in human beings is consistent with these observations and is
in need of further investigation. Conceivably, this mechanism may play a somewhat different
role in humans from what has been observed in most experimental animal models.
Twenty-five years ago, about all that was known about cellular immunity or, as it
was then called, delayed type hypersensitivity, was that it was, in general, a bad
thing. The tuberculin reaction was the paradigm, a violent, often corrosive response
in the tissues of infected animals, probably mediating the destruction of lung tissue
but of arguable protective value. The lesions of leprosy were thought to be similarly
mediated. Louis Dienes had discovered in the 1920s that tissues involved in the
tuberculin reaction were peculiarly hyperreactive to other antigens injected into the
reacting sites, and Jules Freund, about ten years later on (the field moved slowly in
those days) applied this observation for the development ofthe mixed salad ofkilled
tubercle bacilli, mineral oil, and antigen, known as Freund's adjuvants; this was of
course a highly useful aspect of cellular immunity, but only useful for experimental
pathologists. As it turned out, Freund's adjuvants were indispensable for the induc-
tion of allergic encephalomyelitis, the earliest experimental model for autoimmune
disease, characterized by dense aggregates of lymphocytes around foci of myelin
destruction. Later, others produced by the same method a series of other autoim-
mune disorders involving lymphocytes and macrophages and involving, selectively,
thyroid, testis, liver, skin, adrenal, and other organs-all testifying.to the likely in-
volvement ofcellular immunity as a centrally placed mechanism for destroying one's
own organs and tissues, with a high degree of specificity. The field of inquiry was
given the term "immunopathology," and it has been influencing our views of human
disease in medicine ever since, perhaps over-influencing and oversimplifying them as
well. During all this time through the post-World War II period, nothing beneficial
about this sort of immunologic reactivity had been adduced. The phenomenon of
skin graft rejection, and the discovery of the role played by cellular immunity in
histocompatibility and tolerance, opened the way for the understanding of what
lymphocytes actually do for a living, but the teleological question remained hanging
in mid-air. Tissue grafts could be selectively rejected with exquisite, surgical perfec-
tion, down to the last alien cell, one's own cells could be edited away using tissue an-
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All rights of reproduction in any form reserved.tigens and adjuvants, and lymphocytes were known to be primarily responsible, but
what after all was this intended to accomplish in real life? Surely this intricate and
powerful apparatus was not selected in evolution in order to provide experimental
surgeons and pathologists with something to do for a living. The notion that perhaps
cellular immunity had something to do with defense against viruses and some types
of bacteria had not yet emerged.
This is where things stood in the late 1950s: an infallibly accurate device had been
recognized for destroying autografts as well as recognizing and remembering the
specific foreignness of individual populations of cells and destroying them more
rapidly the second time around, but no one knew what it was good for.
In the circumstance, the phenomenon of cellular immunity was fair game for
loose speculation. The possibility was then raised [1] that it might have been de-
signed as a useful and effective mechanism for the early sensing and early elimina-
tion of neoplastic cells, on two assumptions: that cancer cells might be arising in
small clones, in one organ or another, all the time, and that they might always have
something foreign displayed at their surfaces indicating their alien nature. The no-
tion was proposed at a New York symposium in 1957, and, sometime later, Burnet
[2] developed the concept in detail and gave it the name "immunosurveillance."
It seemed to me then, and still does, that some such built-in immunologic
mechanism ought to exist for natural defense against cancer in humans. It had
already been solidly established that experimental animals could be immunized
against syngeneic transplantable tumors, especially tumors known to be caused by
viruses. To be sure, immunization was a tricky business, as likely to cause increased
vulnerability by the phenomenon of enhancement as to produce solid resistance,
depending on the dosage and timing of tumor antigens. What was not known then,
and remains unclear still, was whether preexisting immunity could bring about
resistance to the development of spontaneous cancer in animals. However, there
was, and is, abundant evidence that some strains of inbred mice were much more
susceptible to spontaneous tumors, including tumors caused both by viruses and
chemical carcinogens. Recently, North [3] has found that syngeneic sarcomas in
mice can be eliminated by passive transfer of immune T-lymphocytes, provided that
the population of specific T-suppressor cells is eliminated at the same time.
The idea that differences in genetic resistance might be based on different degrees
of immunologic response seemed reasonable enough 25 years ago, and it seemed a
short step to extrapolate the possibility to humans. There are such things as "cancer
families" in which the incidence of various neoplasms runs considerably higher than
in the general population. Moreover, it has long been known that there are cancer-
prone individuals, in whom two or more quite different types ofcancer will occur in
a lifetime; indeed, a study at Memorial Hospital [4] has revealed that patients with
any given type of cancer are, as a group, statistically much more liable than normal
people to develop a second or even a third tumor of a different kind after they are
surgically cured of the first growth. This is not to be confused with the possible car-
cinogenic effects of chemotherapy: the observation of multiple cancers long
antedates chemotherapy. Children with various types of congenital immunodefi-
ciency are highly vulnerable to neoplasia, mostly leukemia and lymphomas.
The overall incidence of cancer in different human societies, living under
altogether different environmental conditions, also suggests the existence of some
fairly stable form of natural resistance. By and large, around 25 percent of human
beings will develop cancer in a full lifetime in our kind of society. The figures have
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been skewed somewhat in recent decades because of the increased incidence of lung
cancer in cigarette smokers, but, even so, it seems to happen that around 75 percent
of us are, somehow or other, naturally protected against cancer.
There are a few forms of human cancer in which something like immune defense
seems to be operating in the natural course of the disease. One form of skin cancer,
keratoacanthoma, which seems on histological grounds to be a genuine cancer,
regresses spontaneously and vanishes altogether a few weeks or months after its ap-
pearance, without any kind of treatment. Lymphocyte aggregation around the
tumor is a conspicuous feature of the pathology ofthis tumor. Spontaneous regres-
sion has also been observed, although much less frequently, in other tumors,
notably choriocarcinoma and, less often, malignant melanomas; Klein [5], of Buf-
falo, has shown that regression ofmelanomas confined to the skin can be induced by
local injections of BCG into the tumors; skin melanomas at remote sites may regress
at the same tirne, although internal metastases are not affected. From time to time,
rarely but in well-documented circumstances [6], spontaneous regression has been
observed in extensive, metastatic malignancies involving the lungs, liver, and
peritoneal cavity; there are several hundred such cases now recorded in the world
literature-people who have been found at laparotomy to have extensive cancer in
the bowel and liver, been sewed up and sent home to die, and then turn up a few
years later free of cancer. It is not known how such things happen, but the mobiliza-
tion of cellular immunity against the neoplasm is as reasonable a possibility as any
other to be thought of.
What is needed, of course, is a series of human experiments, planned and ex-
ecuted in order to answer the sort ofquestion which automatically raises itself: what
would happen if you were to remove the putative defense mechanism of cellular im-
munity in human beings? Would this affect either the incidence or clinical course of
cancer? As it happens, the experiments have already been done, and continue today.
Malignancies have been occurring with astonishing frequency in patients receiving
grafts of kidneys and hearts in recent years, and the only plausible explanation for
this is the routine, mandatory use of immunosuppressive drugs. At first-in the case
of kidney grafts-these seemed to be the result of using grafts from donors who
themselves had cancer; it was thought that a few stray cancer cells had somehow
come along with the graft. Later on, however, it became clear that a very substantial
number of brand new cancers were occurring in the course ofthe intensive treatment
of the graft recipients with immunosuppressive drugs. The cancers have been of all
types, carcinomas, sarcomas, and lymphomas. Some have appeared in or near the
graft area, others at distant sites. The most remarkable feature of the phenomenon,
apart from the cancers themselves, has been that a few ofthese spontaneous tumors
have regressed when the immunosuppressive drugs were discontinued. On a few oc-
casions, malignant growths the size of a hen's egg or larger, some with already
established lymph node metastases, have been reported to melt away after stopping
the drugs.
All of the transplanted patients who developed neoplasms were routinely main-
tained on immunosuppressive drugs, usually a combination of azathioprine and
prednisone. Krikorian [7] summarized the results of the Stanford experience with
heart transplants three years ago. Out of 143 transplanted patients who survived for
three months or longer, ten developed cancer: sixlymphomas, three carcinomas, and
one acute leukemia. All of these patients were under 40 years of age, which indicates
that the incidence of de novo cancer was really extraordinarily high. For renal
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times the expected rate for the ages involved. In one series of kidney transplants
reviewed by Israel Penn [8] in 1977, 5-6 percent of the patients developed cancer
during the next three to four years. The average age of the recipents was 38. There
were 453 de novo cancers in 432 recipients, meaning multiple cancers in 20 patients.
Over 65 percent of the cancers were epithelial in origin-including skin, lip, uterus,
colon, bladder, lung, breast, kidney, while the other 35 percent were mesenchymal,
principally reticulum cell sarcomas and some leukemias. Less than 1 percent were
Hodgkins.
In another study reported from Australia in 1981, by Sheil et al. [9], 459 patients
received cadaveric renal grafts and were maintained on azothioprine and pred-
nisone. Within one year, 108 (26 percent) developed neoplasms, chiefly squamous
cell cancer of the skin (80 percent of the affected group); in nine of these patients,
the skin cancers exhibited metastases. A smaller cluster (181 patients) were followed
over a five-year period, with a cancer incidence of 43 percent.
Zisbrod [10] reported one patient who developed extensive and rapidly growing
Kaposi's sarcoma eight months after renal transplantation, involving both skin and
gastrointestinal tract. The immunosuppressive drugs were discontinued and replaced
by a rather mild course of anti-cancer drugs, and all of the Kaposi lesions vanished.
It has been reported that the skin lesions ofKaposi's sarcoma will sometimes regress,
although it is a rare event, but this, according to Zisbrod, is the only reported case to
have had total remission of visceral Kaposi's.
Spees [11] reported a patient with an ocular melanoma which appeared one year
after kidneytransplantation. As it happened, the kidneytransplant was unsuccessful
and the drugs were stopped. The patient was maintained on dialysis, and the tumor
remained quiescent for the following 13 months. Then a new renal transplant was
put in place and the drugs resumed. Within three months the melanoma grew so
rapidly that the eye had to be enucleated. In addition, there is a small group of renal
transplant patients in the literature who were known to have had cancer beforehand,
thought to have been cured, in whom recurrence of the cancer with metastases and
death occurred during immunosuppressive therapy.
The greatest trouble with the idea of immunosurveillance is that it cannot be
shown to exist in experimental animals, with the exception of tumors caused by
viruses in which an early immune response either to the virus itself or to antigens
coded by the virus has been shown to be protective. Nude mice, and thymectomized
mice, are no more susceptible to carcinogen-induced cancers, or to spontaneous
cancers, than are normal mice. However, the mechanism responsible for the distinct
difference in susceptibility between different genetic lines of mice remains to be
clarified. There is evidence that at least part of the difference is due to the activity of
cytocidal natural killer lymphocytes, under control of a strong H-2 linked factor in
resistant animals [12]. However, it is by no means clear that the situation in
mice-either with chemical carcinogens, tumor viruses, or transplanted tumors-is
comparable to the situation in man which must exist when the very first nest of
neoplastic cells turns up in a given tissue, long before this microneoplasia has had
time to begin replicating new cells with modulated surface antigens. The frequency
with which small clusters of cells resembling cancer cells are encountered in routine
human autopsy specimens on patients, mostly elderly patients, not suspected ofhav-
ing cancer (the ambiguous and long-debated "carcinomas-in-situ") suggests the
possibility that transformation may be a much more frequent event in human beings
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than can be accounted for by the incidence of successful bona fide cancers. Boyd [6]
summarized the evidence for latent, nonprogressive, possibly transient cancers in
human beings in 1966. The most remarkable observations concern cancer of the pros-
tate. In men over 50, dying from other causes, 25 percent were found to have small,
histologically unquestionable cancer in their prostate glands. In men over 80, the
figure was 50 percent. These incidences are so far in excess of the known occurrence
of clinical cancer in this organ that it must be assumed that many of the cancers
either failed to grow or later regressed. I believe it is true that we, unlike inbred mice,
are constantly producing small nests oftransformed cells in one organ after another,
under environmental or endocrine or viral influences, and getting rid of them effi-
ciently most of the time. Approximately 25 percent of us fail to do this.
It will be of great interest to see what happens in the increasing population of
organ-transplanted patients now undergoing immunosuppression with Cyclosporin-
A. This substance seems to be providing a high degree of protection against graft re-
jection by its relatively selective action on T-helper lymphocytes. To date, most of
the cases of cancer in grafted patients have occurred during treatment with
aziothioprine, and it is possible that some ofthe effect ofthis drug may be the result
of its own mutagenic and carcinogenic properties (although it is difficult to use this
explanation for the appearance of tumors within so short a time after beginning its
administration). In the case of Cyclosporin-A, there is no evidence for car-
cinogenicity; it seems generally accepted that its principal action is directed against
T-lymphocytes. Thus far, five cases of lymphoma have been reported among 300
recipients of kidney grafts maintained on Cyclosporin-A [13]. If other neoplasms,
especially the epithelial carcinomas reported in such high incidence among
azothioprine-treated patients, begin to occur in patients receiving Cyclosporin-A,
this can be taken, in my view, as additional evidence for the notion of im-
munosurveillance as a natural protective mechanism against neoplasia in human be-
ings.
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